What is the 13F Pro Quality Score for LCTX?

13F Pro ranks Lineage Cell Therapeutics, Inc. (LCTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LCTX's current score at https://13fpro.ai/research/LCTX (free sign-up required for the full ranking).

Where does 13F Pro source LCTX data?

All Lineage Cell Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Lineage Cell Therapeutics, Inc. files with the SEC under CIK 876343. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LCTX in?

Lineage Cell Therapeutics, Inc. (LCTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LCTX research updated on 13F Pro?

LCTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lineage Cell Therapeutics, Inc.(LCTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 876343 LCTX stock profile & AI dashboard →

13F Pro Quality Score

6.9/100

Rank #2,838 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

1.1/100

Profitability

3.0/100

Balance Sheet

2.2/100

Earnings Quality

30.0/100

Free Cash Flow

4.7/100

Institutional Flow

54.8/100

Revenue Scale

3.5/100

Dilution Risk

6.0/100

LCTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lineage Cell Therapeutics, Inc. (LCTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LCTX at 6.9/100 on a 32-signal composite quality model, placing it at rank #2,838 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.1) and balance sheet strength (2.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Lineage Cell Therapeutics, Inc. reports quarterly revenue of $1.7M, net income of $-4.8M, free cash flow of $-8.1M. Top institutional holders of LCTX by reported 13-F value include BROADWOOD CAPITAL, VANGUARD CAPITAL MANAGEMENT, Defender Capital,, based on the most recent SEC filings. LCTX trades on the NYSE exchange and files with the SEC under CIK 876343. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LCTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lineage Cell Therapeutics, Inc. directly from SEC EDGAR. Lineage Cell Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 31 since 2024, currently 6.9 — a declining long-term trajectory across 15 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.7M

Net Income

Q1 2026

$-4.8M

Free Cash Flow

Q1 2026

$-8.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+62.7% YoY

$14.6MFY 2025

FY20 $1.8MFY21 $4.3MFY23 $8.9MFY25 $14.6M

Net Income

-195.7% YoY

$-63.5MFY 2025

FY20 $-20.6MFY21 $-43.0MFY23 $-21.5MFY25 $-63.5M

Operating Income

-48.1% YoY

$-36.6MFY 2025

FY20 $-26.4MFY21 $-49.2MFY23 $-24.7MFY25 $-36.6M

EPS (Diluted)

-133.3% YoY

$-0.28FY 2025

FY20 —FY21 —FY23 $-0.12FY25 $-0.28

Total Assets

+11.4% YoY

$112.6MFY 2025

FY20 $107.9MFY21 $174.5MFY23 $101.0MFY25 $112.6M

Op. Cash Flow

+33.8% YoY

$-18.9MFY 2025

FY20 $-19.8MFY21 $-23.6MFY23 $-28.6MFY25 $-18.9M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$14.6M +62.7%	$8.9M +106.1%	$4.3M +137.7%	$1.8M -48.1%	$3.5M -29.5%	$5.0M
Net Income	$-63.5M -195.7%	$-21.5M +50.1%	$-43.0M -108.3%	$-20.6M -76.4%	$-11.7M +74.5%	$-46.0M
Operating Income	$-36.6M -48.1%	$-24.7M +49.7%	$-49.2M -86.1%	$-26.4M +32.0%	$-38.9M +7.0%	$-41.8M
EPS (Diluted)	$-0.28 -133.3%	$-0.12	—	—	—	—
Total Assets	$112.6M +11.4%	$101.0M -42.1%	$174.5M +61.7%	$107.9M -14.0%	$125.5M +23.4%	$101.7M
Operating Cash Flow	$-18.9M +33.8%	$-28.6M -21.2%	$-23.6M -19.3%	$-19.8M +38.2%	$-31.9M -3.4%	$-30.9M

AI Insight: LCTX Financial Trends

Lineage Cell remains pre-commercial with volatile losses; Q4 2025 marked rare profitability but reversed in Q1 2026.

• Revenue remains negligible at $2–7M across all quarters; Q4 2025 peaked at $7M then fell to $2M in Q1 2026.

• Net income swung to $1M profit in Q4 2025 after $30M losses in Q2 and Q3 2025, then returned to $-5M in Q1 2026.

• Equity eroded from $79M (Q1 2025) to $22M (Q3 2025), recovered to $54M by Q1 2026; balance sheet remains under pressure.

⚠ Operating cash burn consistent at $4–8M per quarter; Q1 2026 deteriorated to $-8M, signaling accelerating cash consumption.

⚠ Q4 2025 profitability was isolated anomaly; Q1 2026 reverted to $-5M net loss amid continued R&D spending.

AI Insight: LCTX Ratio Trends

Lineage swung to Q4 2025 profitability (NPM +12.9%) but immediately reversed into losses in Q1 2026, signaling unsustainable momentum.

• Q4 2025 NPM jumped to +12.9% from -102.8% operating margin, first positive quarter on record in dataset.

• Q1 2026 ROE collapsed to -35.7% from Q4's +7.6%; ROIC deteriorated to -56.4% from -58.8%, reversing gains.

• Operating margin remains deeply negative across most periods: -99.1% to -178.2% in 2024–2025, with Q4 2025 sole exception.

⚠ Q4 2025 profitability appears anomalous; reversion to -35.7% ROE in Q1 2026 raises questions about sustainability.

⚠ Persistent negative ROIC across all periods (-23% to -71%) indicates value destruction; no inflection evident.

Get alerted when LCTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lineage Cell Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LCTX

BROADWOOD CAPITAL INC
$78.3M49,560,992 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.1M8,318,685 sh
Defender Capital, LLC.
$10.6M6,729,599 sh
MILLENNIUM MANAGEMENT LLC
$8.8M5,561,374 sh
RAFFLES ASSOCIATES LP
$8.5M5,362,788 sh
FIFTH THIRD BANCORP
$7.3M4,600,000 sh
BlackRock, Inc.
$6.1M3,864,757 sh
ARMISTICE CAPITAL, LLC
$5.0M3,182,799 sh
MARSHALL WACE, LLP
$4.8M3,065,033 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.0M2,523,114 sh

Fund	Value	Shares
BROADWOOD CAPITAL INC	$78.3M	49,560,992
VANGUARD CAPITAL MANAGEMENT LLC	$13.1M	8,318,685
Defender Capital, LLC.	$10.6M	6,729,599
MILLENNIUM MANAGEMENT LLC	$8.8M	5,561,374
RAFFLES ASSOCIATES LP	$8.5M	5,362,788
FIFTH THIRD BANCORP	$7.3M	4,600,000
BlackRock, Inc.	$6.1M	3,864,757
ARMISTICE CAPITAL, LLC	$5.0M	3,182,799
MARSHALL WACE, LLP	$4.8M	3,065,033
GEODE CAPITAL MANAGEMENT, LLC	$4.0M	2,523,114

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LCTX on your watchlist

Track score changes the day Lineage Cell Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LCTX a good stock to buy?

13F Pro's AI-powered analysis of Lineage Cell Therapeutics, Inc. (LCTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LCTX are available on the LCTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LCTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LCTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lineage Cell Therapeutics, Inc.'s investment landscape.